Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Care | Study protocol

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments

Authors: Jason S. Haukoos, Sarah E. Rowan, James W. Galbraith, Richard E. Rothman, Yu-Hsiang Hsieh, Emily Hopkins, Rachel A. Houk, Matthew F. Toerper, Kevin F. Kamis, Jake R. Morgan, Benjamin P. Linas, Alia A. Al-Tayyib, Edward M. Gardner, Michael S. Lyons, Allison L. Sabel, Douglas A. E. White, David L. Wyles, for The DETECT Hep C Trials Investigators

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Early identification of HCV is a critical health priority, especially now that treatment options are available to limit further transmission and provide cure before long-term sequelae develop. Emergency departments (EDs) are important clinical settings for HCV screening given that EDs serve many at-risk patients who do not access other forms of healthcare. In this article, we describe the rationale and design of The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial.

Methods

The DETECT Hep C Screening Trial is a multi-center prospective pragmatic randomized two-arm parallel-group superiority trial to test the comparative effectiveness of nontargeted and targeted HCV screening in the ED with a primary hypothesis that nontargeted screening is superior to targeted screening when identifying newly diagnosed HCV. This trial will be performed in the EDs at Denver Health Medical Center (Denver, CO), Johns Hopkins Hospital (Baltimore, MD), and the University of Mississippi Medical Center (Jackson, MS), sites representing approximately 225,000 annual adult visits, and designed using the PRECIS-2 framework for pragmatic trials. When complete, we will have enrolled a minimum of 125,000 randomized patient visits and have performed 13,965 HCV tests. In Denver, the Screening Trial will serve as a conduit for a distinct randomized comparative effectiveness trial to evaluate linkage-to-HCV care strategies. All sites will further contribute to embedded observational studies to assess cost effectiveness, disparities, and social determinants of health in screening, linkage-to-care, and treatment for HCV.

Discussion

When complete, The DETECT Hep C Screening Trial will represent the largest ED-based pragmatic clinical trial to date and all studies, in aggregate, will significantly inform how to best perform ED-based HCV screening.

Trial registration

ClinicalTrials.gov ID: NCT04003454. Registered on 1 July 2019.
Appendix
Available only for authorised users
Literature
1.
go back to reference Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.CrossRef Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.CrossRef
2.
go back to reference Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9:e101554.CrossRef Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9:e101554.CrossRef
3.
go back to reference Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.CrossRef Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.CrossRef
4.
go back to reference Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.CrossRef Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.CrossRef
5.
go back to reference Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRef Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.CrossRef
6.
go back to reference Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRef Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRef
7.
go back to reference Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61:783–9.CrossRef Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61:783–9.CrossRef
8.
go back to reference Rowan SE, Muething L, Spielmann K, et al. The yield of birth cohort screening for hepatitis C in community health centers. J Gen Intern Med. 2019;34:2003–4.CrossRef Rowan SE, Muething L, Spielmann K, et al. The yield of birth cohort screening for hepatitis C in community health centers. J Gen Intern Med. 2019;34:2003–4.CrossRef
9.
go back to reference Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(R-19):1-39. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(R-19):1-39.
10.
go back to reference Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.PubMed Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.PubMed
11.
go back to reference Moyer VA, Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349–57.CrossRef Moyer VA, Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349–57.CrossRef
12.
go back to reference Kierzek G, Aslangul E, Le Guerroue G, Le Jeunne C, Pourriat JL. Feasibility of a nontargeted active opt-in HIV, HBV, and HCV testing in an academic emergency department. Eur J Emerg Med. 2009;16:111–2.CrossRef Kierzek G, Aslangul E, Le Guerroue G, Le Jeunne C, Pourriat JL. Feasibility of a nontargeted active opt-in HIV, HBV, and HCV testing in an academic emergency department. Eur J Emerg Med. 2009;16:111–2.CrossRef
13.
go back to reference Galbraith JW, Anderson ES, Hsieh YH, et al. High prevalence of hepatitis C infection among adult patients at four urban emergency departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017. MMWR Morb Mortal Wkly Rep. 2020;69:569–74.CrossRef Galbraith JW, Anderson ES, Hsieh YH, et al. High prevalence of hepatitis C infection among adult patients at four urban emergency departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017. MMWR Morb Mortal Wkly Rep. 2020;69:569–74.CrossRef
14.
go back to reference Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.PubMed Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.PubMed
15.
go back to reference Pitts SR, Carrier ER, Rich EC, Kellermann AL. Where Americans get acute care: increasingly, it’s not at their doctor’s office. Health affairs. 2010;29:1620–9.CrossRef Pitts SR, Carrier ER, Rich EC, Kellermann AL. Where Americans get acute care: increasingly, it’s not at their doctor’s office. Health affairs. 2010;29:1620–9.CrossRef
16.
go back to reference Haukoos JS, Hopkins E, Hull A, et al. HIV testing in emergency departments in the United States: a national survey. Ann Emerg Med. 2011;58(Suppl 1):S10–6.CrossRef Haukoos JS, Hopkins E, Hull A, et al. HIV testing in emergency departments in the United States: a national survey. Ann Emerg Med. 2011;58(Suppl 1):S10–6.CrossRef
17.
go back to reference Haukoos JS, Lyons MS, Rothman RE. The evolving landscape of HIV screening in the emergency department. Ann Emerg Med. 2018;72:54–6.CrossRef Haukoos JS, Lyons MS, Rothman RE. The evolving landscape of HIV screening in the emergency department. Ann Emerg Med. 2018;72:54–6.CrossRef
18.
go back to reference Galbraith JW, Franco RA, Donnelly JP, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology. 2015;61:776–82.CrossRef Galbraith JW, Franco RA, Donnelly JP, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology. 2015;61:776–82.CrossRef
19.
go back to reference Galbraith JW. Hepatitis C virus screening: an important public health opportunity for United States emergency departments. Ann Emerg Med. 2016;67:129–30.CrossRef Galbraith JW. Hepatitis C virus screening: an important public health opportunity for United States emergency departments. Ann Emerg Med. 2016;67:129–30.CrossRef
20.
go back to reference Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381:91–2.CrossRef Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381:91–2.CrossRef
21.
go back to reference Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.CrossRef Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.CrossRef
22.
go back to reference Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464–75.CrossRef Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464–75.CrossRef
23.
go back to reference Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37.CrossRef Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10:37.CrossRef
24.
go back to reference Hepatitis C. guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRef Hepatitis C. guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRef
25.
go back to reference Haukoos JS, Lyons MS, Rothman RE, et al. Comparison of HIV screening strategies in the emergency department: a randomized clinical trial. JAMA Netw Open. 2021;4:e2117763.CrossRef Haukoos JS, Lyons MS, Rothman RE, et al. Comparison of HIV screening strategies in the emergency department: a randomized clinical trial. JAMA Netw Open. 2021;4:e2117763.CrossRef
26.
go back to reference Gould AL. Sample size re-estimation: recent developments and practical considerations. Stat Med. 2001;20:2625–43.CrossRef Gould AL. Sample size re-estimation: recent developments and practical considerations. Stat Med. 2001;20:2625–43.CrossRef
27.
go back to reference Snijders T, Bosker R. Multilevel analysis: an introduction to basic and advanced multilevel modeling. Thousand Oaks: SAGE Publications, Inc.; 2002. Snijders T, Bosker R. Multilevel analysis: an introduction to basic and advanced multilevel modeling. Thousand Oaks: SAGE Publications, Inc.; 2002.
28.
go back to reference Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
Metadata
Title
The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments
Authors
Jason S. Haukoos
Sarah E. Rowan
James W. Galbraith
Richard E. Rothman
Yu-Hsiang Hsieh
Emily Hopkins
Rachel A. Houk
Matthew F. Toerper
Kevin F. Kamis
Jake R. Morgan
Benjamin P. Linas
Alia A. Al-Tayyib
Edward M. Gardner
Michael S. Lyons
Allison L. Sabel
Douglas A. E. White
David L. Wyles
for The DETECT Hep C Trials Investigators
Publication date
01-12-2022
Publisher
BioMed Central
Keywords
Care
Hepatitis C
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06265-1

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue